Review article · 2022 · Open access
Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
Molecules, 27(24), 8828 · Published 12 December 2022 · DOI 10.3390/molecules27248828
In brief
“Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future” is a 2022 review article by Rui Li and 5 co-authors, published in Molecules. OpenAlex counts 75 citations as of 19 November 2026, which puts it in the top 2% of works published in 2022 by citations. It is open access under a CC BY licence: the full text is free to read at Molecules.
- Citations
- 75
- Most cited in
- 2025 (37)
- Field-weighted impact
- 1.46
- References
- 95
- Authors
- 6
Abstract
The PROteolysis TArgeting Chimeras (PROTACs) is an innovative technique for the selective degradation of target proteins via the ubiquitin-proteasome system. Compared with traditional protein inhibitor drugs, PROTACs exhibit advantages in the efficacy and selectivity of and in overcoming drug resistance in cancer therapy, providing new insights into the discovery of anti-cancer drugs. In the last two decades, many PROTAC molecules have been developed to induce the degradation of cancer-related targets, and they have been subjected to clinical trials. Here, we comprehensively review the historical milestones and latest updates in PROTAC technology. We focus on the structures and mechanisms of PROTACs and their application in targeting tumor-related targets. We have listed several representative PROTACs based on CRBN, VHL, MDM2, or cIAP1 E3 ligases, and PROTACs that are undergoing anti-cancer clinical trials. In addition, the limitations of the current research, as well as the future research directions are described to improve the PROTAC design and development for cancer therapy.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Li, R., Liu, M., Yang, Z., Li, J., Gao, Y., & Tan, R. (2022). Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future. Molecules, 27(24), 8828. https://doi.org/10.3390/molecules27248828
MLA 9
Li, Rui, et al. “Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.” Molecules, vol. 27, no. 24, 2022, p. 8828. https://doi.org/10.3390/molecules27248828.
Chicago
Li, Rui, Miao Liu, Zhenya Yang, Jiao Li, Yuxin Gao, and Ruirong Tan. 2022. “Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.” Molecules 27 (24): 8828. https://doi.org/10.3390/molecules27248828.
Harvard
Li, R. et al. (2022) ‘Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future’, Molecules, 27(24), p. 8828. doi:10.3390/molecules27248828.
IEEE
R. Li, M. Liu, Z. Yang, J. Li, Y. Gao, and R. Tan, “Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future,” Molecules, vol. 27, no. 24, p. 8828, 2022, doi: 10.3390/molecules27248828.
BibTeX
@article{li2022proteolysis,
title = {{Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future}},
author = {Li, Rui and Liu, Miao and Yang, Zhenya and Li, Jiao and Gao, Yuxin and Tan, Ruirong},
journal = {Molecules},
year = {2022},
volume = {27},
number = {24},
pages = {8828},
doi = {10.3390/molecules27248828},
url = {https://doi.org/10.3390/molecules27248828}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 7 | |
| 2024 | 18 | |
| 2025 | 37 | |
| 2026 | 12 |
Its field-weighted citation impact is 1.46: it has been cited 1.46 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- PROTACs
- protein degradation
- ubiquitin-proteasome system
- cancer therapy
- drug resistance
- cereblon
- VHL
- MDM2
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Li, R., Liu, M., Yang, Z., Li, J., Gao, Y., & Tan, R. (2022). Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future. Molecules, 27(24), 8828. https://doi.org/10.3390/molecules27248828
How many times has this paper been cited?
75 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Molecules: sign in and open the PDF from this page.
Who wrote this paper?
Rui Li, Miao Liu, Zhenya Yang, Jiao Li, Yuxin Gao, Ruirong Tan.
What is the DOI of this paper?
10.3390/molecules27248828, permanently at https://doi.org/10.3390/molecules27248828. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.